PT  - JOURNAL ARTICLE
AU  - Walle, Thomas
AU  - Bajaj, Sunanjay
AU  - Kraske, Joscha A.
AU  - Rösner, Thomas
AU  - Cussigh, Christiane S.
AU  - Kälber, Katharina A.
AU  - Müller, Lisa Jasmin
AU  - Strobel, Sophia Boyoung
AU  - Burghaus, Jana
AU  - Kallenberger, Stefan
AU  - Stein-Thöringer, Christoph
AU  - Jenzer, Maximilian
AU  - Schubert, Antonia
AU  - Kahle, Steffen
AU  - Williams, Anja
AU  - Hoyler, Birgit
AU  - Zielske, Lin
AU  - Skatula, Renate
AU  - Sawall, Stefanie
AU  - Leber, Mathias F.
AU  - Kunes, Russell Z.
AU  - Krisam, Johannes
AU  - Fremd, Carlo
AU  - Schneeweiss, Andreas
AU  - Krauss, Jürgen
AU  - Berger, Anne Katrin
AU  - Haag, Georg M.
AU  - Zschäbitz, Stefanie
AU  - Halama, Niels
AU  - Springfeld, Christoph
AU  - Kirsten, Romy
AU  - Hassel, Jessica C.
AU  - Jäger, Dirk
AU  - ,
AU  - Ungerechts, Guy
TI  - Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but clinically inapparent in cancer patients under immune checkpoint therapy
AID  - 10.1101/2021.12.08.21267430
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.08.21267430
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267430.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267430.full
AB  - Cancer patients frequently receive immune checkpoint therapies (ICT) which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a cancer patient who received the BTN162b2 vaccine under ICT. Here, we analyzed adverse events (AEs) in patients of various solid tumor types undergoing (n=64) or not undergoing (n=26) COVID-19 vaccination under ICT as an exploratory endpoint of a prospectively planned cohort study. We did not observe clinically relevant CRS after vaccination (95% CI [0,0.056]). Short term (<4 weeks) serious AEs were rare (12.5%) and overall AEs under ICT were comparable to unvaccinated patients. Despite the absence of CRS symptoms, we observed a pairwise-correlated set of CRS-associated cytokines upregulated in 42% of patients after vaccination and ICT (>1.5fold). Hence, clinically meaningful CRS appears to be rare in cancer patients under ICT and elevated serum cytokine levels are common but not sufficient to establish CRS diagnosis.Competing Interest StatementThomas Walle reports previous and current stock ownership of various pharmaceutical companies manufacturing SARS-CoV-2 vaccines and diagnostics including BionTech, Astra-Zeneca and Roche. Thomas Walle reports research support from CanVirex, Basel, Switzerland, a company developing viral vector-based immunotherapies and vaccines (financial support for blood sampling materials). Guy Ungerechts is founder and current CMO/CSO of CanVirex. All other authors report no conflicts of interest.Funding StatementDKFZ Clinician Scientist Program, supported by the Dieter Morszeck Foundation to T.W and A.S. National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany CanVirex, Basel, Switzerland to T.W./G.U. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial received institutional ethics review board approval at Ethics Commission I Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany (S-373/2020, S-207/2005,) and Ethics Commission II Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (2021-567).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and code is supplied with the manuscript (https://github.com/wallet-maker/ANTICIPATE_COVID-19.git). Patient material of patients who have given consent for further analyses can be requested after approval of Ethics Commission I, Medical Faculty Heidelberg, Heidelberg University. No custom materials have been generated during this study. https://github.com/wallet-maker/ANTICIPATE_COVID-19.git